Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Ovarian Cancer
Related studies linked through entity extraction aliases.
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Status
- RECRUITING
- Phase
- NA
Implementation of New Models of Ovarian Carcinoma Resistant to Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Status
- RECRUITING
- Phase
- PHASE1
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?
- Status
- RECRUITING
- Phase
- PHASE1
Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Predictors of Cognitive Decline and Delirium in Older Women With Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）
- Status
- NOT_YET_RECRUITING
- Phase
- N/A